- Venture Capital Investment Trends in Pharma, Q3 2025 Report - Investments Reach $5 Billion, Up 9.9% Quarter-on-Quarter as Oncology Leads with 69 Deals and 231 Investors
- Sitryx to participate in upcoming healthcare investor conferences
- BBOT Reports Third Quarter 2025 Financial Results and Update on Corporate Progress
- Annovis Provides Corporate Updates and Reports Third Quarter 2025 Financial Results
- Pharma M&A Trends Report, Q3 2025: Oncology Emerged As the Leading Therapeutic Area Recording 32 Deals
- Rozanolixizumab (Rystiggo) Market Research 2025: Rising Prevalence of Autoimmune and Neurological Disorders, Which Demand Targeted and Effective Therapeutic Options Fueling Expansion
- Assembly Biosciences Reports Third Quarter 2025 Financial Results and Recent Updates
- U.S. $882.63 Bn Pharmaceutical Market Trends, Competition, Opportunities & Forecasts, 2030F - Companies Focused on Value-driven, Patient-centric Strategies Will Thrive Despite Pricing Pressures
- EU (European Union) Proposed Pharmaceutical Legislation Changes Training Course: Compliance, Market Authorisations, and Managing Drug Development and Post-approval Obligations (Online: Jan 19, 2026)
- aTyr Pharma to Present at Piper Sandler 37th Annual Healthcare Conference
